PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
+0.26 (+0.75%)
At close: 4:00PM EDT

35.00 +0.13 (0.37%)
Pre-Market: 5:10AM EDT

Stock chart is not supported by your current browser
Previous Close34.61
Bid34.80 x 3200
Ask35.00 x 3200
Day's Range34.82 - 35.12
52 Week Range33.97 - 46.47
Avg. Volume25,550,303
Market Cap192.868B
Beta (3Y Monthly)0.37
PE Ratio (TTM)16.11
EPS (TTM)2.16
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & Yield1.44 (4.16%)
Ex-Dividend Date2019-08-01
1y Target Est42.82
Trade prices are not sourced from all markets
  • 3 Dividend Stocks That Pay Better Than Coca-Cola
    Motley Fool

    3 Dividend Stocks That Pay Better Than Coca-Cola

    Coke's yield is a juicy 3% or so. But you can do better! Here are stocks every bit as enticing, if not more so.

  • Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks
    Investor's Business Daily

    Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks

    Dow Jones' Pfizer is making a big push into gene therapy manufacturing as it tackles Duchenne muscular dystrophy and hemophilia B, rivaling Sarepta Therapeutics and Spark Therapeutics.


    Record Stock Buybacks Fueled by Debt and Cash

    A review of several companies' buyback activity Continue reading...

  • Business Wire

    U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). The application has also been granted Priority Review, a designation given to those applications for drugs that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications.

  • Pfizer invests $500 million in expanding gene therapy facility

    Pfizer invests $500 million in expanding gene therapy facility

    The investment will add additional capacity and capabilities to a facility that makes some of Pfizer's most closely watched experimental treatments. The Sanford plant manufactures therapies used for the company's late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies.

  • Teva Launches Generic Version of Mylan's EpiPen for KIds

    Teva Launches Generic Version of Mylan's EpiPen for KIds

    Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.

  • AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study

    AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study

    AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.

  • Pfizer to build $500M facility in Sanford, create hundreds of jobs
    American City Business Journals

    Pfizer to build $500M facility in Sanford, create hundreds of jobs

    Leaning into its success with gene therapy, Pfizer (NYSE: PFE) has announced a half-billion dollar expansion of its Sanford footprint, which is expected to bring 300 jobs to the region.

  • Business Wire

    Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina

    Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would expand the company’s presence in North Carolina, where there are currently more than 3,600 Pfizer colleagues, including 650 in Sanford.

  • Trade of the Day: Pfizer Stock Is Flashing Attractive Buy Signals

    Trade of the Day: Pfizer Stock Is Flashing Attractive Buy Signals

    Recently, shares of Pfizer (NYSE:PFE) dropped 20% in a straight line following the company's latest earnings report. As a result, PFE stock has reached extreme oversold readings that -- in combination with other factors -- could lead to a pop in the stock.Source: Manuel Esteban / I often share trade ideas where a steep rally or selloff leads to parabolic rally/selling. I find such moves give traders high probability trades in the other direction for quick profits. However, when such a move also coincides with a more structural factor, then a trade idea may even turn into an intermediate or longer-term investment.Before looking at the Pfizer stock charts let me point out that the current low-yielding global environment in bonds (government and corporate) is pushing more investors into riskier assets and out in duration.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, one part of the equity market that still offers good reward-to-risk is quality stocks that pay dividends, such as PFE stock. The recent plunge in PFE stock now has it sporting a 4% dividend yield, which given the aforementioned yield environment, looks increasingly attractive. And after speaking to other investors, I am not alone in this view.With Pfizer stock's dividend yield in mind, let us look at some charts. PFE Stock ChartsWe start off with the multi-year weekly chart where we see that the selling in Pfizer stock, which started in November 2018, reached extremes from a momentum perspective by mid August 2019. At the bottom of the chart, I added the MACD and RSI momentum/trend oscillators, which are deeply oversold.Also note that while PFE stock did break out of its multi-year, up-trending channel, it has reached important horizontal support around the mid $30's, where it could begin to stabilize and bounce over time.On the daily chart, Pfizer stock is also deeply oversold and we see more clearly the horizontal support area it has reached. While the stock could see some more downside given the momentum trends, it looks to me like the recent rate of change is not sustainable and will begin to slow and ultimately lead to a meaningful bounce, if not a trend reversal.Active investors and traders could look to buy PFE stock around the mid $30's with a first upside target at $37 and using a stop loss at $33.50.My clients and I prefer to structure a trade in the highest probability manner, which, in this case, means selling a very specific options spread in PFE stock.In order to teach this special options trade I am holding a webinar for InvestorPlace readers on Wednesday Aug. 21. Register here.Join Serge in an exclusive live webinar: The steady income options strategy. Register HERE. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Trade of the Day: Pfizer Stock Is Flashing Attractive Buy Signals appeared first on InvestorPlace.

  • Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

    Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

    Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.

  • Bayer Sells Animal Health Division to Elanco: Now What?

    Bayer Sells Animal Health Division to Elanco: Now What?

    On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

  • 3 Healthcare Stocks to Trade: UNH, JNJ and PFE

    3 Healthcare Stocks to Trade: UNH, JNJ and PFE

    Even under normal circumstances, the healthcare stocks are prone to headline risk. Case in point, what happened to Sarepta (NASDAQ:SRPT) last night when the stock fell 15% on FDA news. Add to it that the U.S. is approaching another round of elections, and it makes healthcare stocks even riskier than normal -- through no fault of their own.In late June, I discussed three healthcare stocks to buy and for the most part the trades paid quickly. But since then, the stock markets in general had several mini corrections. We had fear flashes over geopolitical headlines, China's currency crisis and most recently, a bond-yield crash. So it's only fair to revisit those names again as the dust is settling. * 10 Undervalued Stocks With Breakout Potential So today we are discussing United Health (NYSE:UNH), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ) stocks. I'll start with my conclusion first. All three are still good stocks to buy at these levels -- but for different reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Johnson & Johnson is a long-time American success story. They are a global household name and their products are ubiquitous. From a valuation perspective, JNJ stock is relatively cheap because it has a modest price-to-earnings (P/E) ratio and pays a decent dividend.JNJ could be cheaper, but this is a management team that has proven itself through thousands of headline worries. The current headlines are nothing new for JNJ. So they have nothing but a temporary effect on the overall trajectory of JNJ stock.That said, Johnson & Johnson is still a buy here for anyone who's looking to add this sector to their portfolio. It is important to note that the company is probably past its talcum-powder headline risk by now even though it's not officially resolved. So I wouldn't take a full position all at once. Alternatively, I can sell puts below the current JNJ stock price to generate income from the intrinsic value of JNJ stock this way I don't even need a rally to win. United Health (UNH)United Health stock has performed the best of the three healthcare stocks since my last write up. It had an immediate 9% spike so from a trading perspective that was good timing.In addition, the overall thesis on UNH stock since then has not changed. It is still trailing the S&P 500 year-to-date. But over the last five years, UNH stock is up 180%, which is four times better than the S&P.After the July spike, UNH stock price faded the rally, but is has fallen into the same support zone from which it broke out. So this is the opportunity for the bulls to rinse-and-repeat another run.Technically speaking, UNH range is tightening into a point, so a move is coming in either direction. It is setting lower-highs and higher-lows at a point that coincides with the 12 month point-of- control for the stock. This is significant because this is literally where bulls and bears have agreed the most.So they will fight it out hard at this price once more and create support. As long as UNH stock holds above $240 per share, the bulls have a shot at retesting $260 or higher. There will be resistance along the way perhaps at $255 and most certainly at $256.50. * 10 Mid-Cap Dividend Stocks to Buy Now Conversely, there is the threat that the bears are able to break below $240 per share. If that happens, it could turn into a bearish head-and-shoulder pattern to target $224 per share. This is not a forecast but it's definitely a scenario that exists currently below UNH stock price. Pfizer (PFE)Pfizer stock was once bulletproof, but it can't even find footing of late. But maybe this time will be different. From current levels Pfizer stock can mount a revenge rally. Clearly so far, its stock performance metrics are poor so this has a lot of hopium tied to it.So this is definitely a tactical trade, and it should have a hard stop below $34 per share. This inadvertently is also a long-term five-year-old pivot point that also happens to be the point of control for that same period. So mathematically speaking, this is where bulls and bears love to disagree. This congestion should act as support.Simply put, if I buy PFE stock here, I literally have more upside potential than downside risk based on the 5-year price history. Fundamentally speaking, PFE is not expensive selling at 17 P/E and three times book. Yes, it can get cheaper, but this trade set up is tactical, so fundamentals don't matter as much for the short term.Longer-term, the Pfizer management team needs to re-earn Wall Street trust so that trades like this one would be with conviction. Maybe then the bulls will be able to drag the PFE stock out of the dumps and back in line with the overall stock market or at least its sector.Nicolas Chahine is the managing director of As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Healthcare Stocks to Trade: UNH, JNJ and PFE appeared first on InvestorPlace.

  • Pfizer-backed cancer treatment innovator SpringWorks eyes $115M IPO
    American City Business Journals

    Pfizer-backed cancer treatment innovator SpringWorks eyes $115M IPO

    SpringWorks plans to list on the Nasdaq as “SWTX.” The Stamford, Connecticut-based firm has yet to report any revenue, and it reported a loss of $17.8 million in 2018. The startup has yet to spend all of its $103 million series A capital, and currently $185.3 in cash and cash equivalents remain from its series B. Bain Capital is also an investor in SpringWorks. SpringWorks was actually founded by former Pfizer President Lara Sullivan.

  • 3 Great Active Mutual Funds for the Current Environment

    3 Great Active Mutual Funds for the Current Environment

    There's a lot of debate over using active mutual funds versus their passive cousins. Much of that debate has low-cost index ETFs and mutual funds winning the fight. The truth is, most active mutual funds and their managers tend to underperform passive vehicles such as the iShares S&P 500 Index (NYSEARCA:IVV).However, investors shouldn't be so quick to throw away active mutual funds from their portfolios. There are situations when being active can pay some serious benefits. This is especially true in a volatile and rocky time such as this.For one thing, active funds don't have to stick to a certain basket of stocks. They can flee to cash when the market gets rough to avoid losses. At the same time, they can use down days to scoop up bargains. Moreover, multi-asset and go-anywhere funds don't have to stick out in stocks. They can go get a good return in any asset class -- stocks, bonds, you name it.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Undervalued Stocks With Breakout Potential The reality is, there are plenty of reasons to go active when the market gets wonky like this. Ignoring active mutual funds could be a recipe for disaster when volatility spikes and the market trends downwards. And with that, here are three top active mutual funds worth buying today. BlackRock Global Allocation Fund (MDLOX)Source: David Tran Photo / "Unconstrained in search of opportunity." That's how the BlackRock Global Allocation Fund (MUTF:MDLOX) bills itself. For nearly 30 years, the team at MDLOX has been combing the world's markets in search of better returns and they have succeeded in spades.With nearly $26 billion in assets, MDLOX is one of the largest go-anywhere mutual funds on the planet. Its wide-sweeping mandate allows it to buy stocks and bonds from nearly 40 countries as well as plenty of non-traditional asset classes.The fund's investment committee of more than 29 individuals aligns its portfolio with their general macroeconomic predictions. This has the fund changing its holdings as the market shifts direction or the managers see opportunities. In this case, a shift towards volatility and lower global economic conditions have it allocating more towards U.S. fixed-income assets of quality. Currently, the fund has roughly 65% of assets in stocks and about 30% in bonds.However, this could and will shift if the overall global economic situation changes.MDLOX's mandate has served investors well. The fund has long held a Morningstar Bronze Medal as well as top scores from Lipper. This has translated into some strong returns for the fund. Since its inception in 1994, the fund has managed to score a 9.74% average annual return. The best part is that it has managed to do just that with lower overall volatility than the S&P 500.In the end, MDLOX is a wonderful core active mutual fund for investors and it has proven itself over time. Expenses run 1.08%- or $108 per $10,000 invested. Many brokerages offer it without a sales charge and low minimums. T. Rowe Price Equity Income (PRFDX)Source: Shutterstock Dividends remain a great way to beat market volatility and get through the current environment. It's here that active mutual funds can shine. As the market dips, yields on quality dividend stocks go up. Active managers can snag these higher yields and quality stocks often on the cheap. A great fund to take advantage of this fact is T. Rowe Price Equity Income (MUTF:PRFDX).PRFDX focuses its attention on large-cap stocks here in the U.S. that pay dividends. However, the focus isn't just on headline yield. Manager John Linehan and his team are value investors at heart, and put more emphasis on quality over quantity. To meet the test, stocks have growing revenues, low debt levels and improving profit margins to be considered. Particular attention is made to price paid -- P/E, P/B, P/S ratios -- for shares. This conservative value investment approach is specifically done to limit potential downside and volatility over time.This focus on quality and value creates a rather concentrated portfolio. The fund stretches its nearly $21 billion dollars over just 127 different names including Pfizer (NYSE:PFE), utility Southern (NYSE:SO) and Microsoft (NASDAQ:MSFT).The focus on quality dividends has also worked wonders in the returns department. Over the last ten years, PRFDX has managed to return over 12% annually. With a big part of that return coming from dividends. And with the fund adding value over its benchmark in the recent bouts of volatility this year, it's worthy of a portfolio addition. * 10 Mid-Cap Dividend Stocks to Buy Now Expenses for the active mutual fund run at just 0.64%. Nuveen Preferred Securities and Income Fund (NPSAX)Source: Shutterstock With everyone running to safety these days, bond yields aren't exactly returning anything. Right now, you can score a 10-year Treasury bond paying about 1.67% in interest payments. That's not great at all. But holding too much in equities could make for a bumpy ride. The best bet? Combine them in preferred stock.Blending both attributes of equities and bonds, preferred stock provides a happy medium of high returns and lower risk. One of the best active mutual funds to dabble in the sector is the Nuveen Preferred Securities and Income Fund (MUTF:NPSAX).NPSAX combs the full gamut of preferred stocks to find values. That includes common $25 par issued retail preferreds as well as institutional $1,000 par valued stocks. Moreover, the team at Nuveen will search for deals across the entire credit spectrum and even internationally for bargains or high yields. the idea is to optimize value and create a balance between risk and reward. That has worked wonders for the active mutual fund -- with NPSAX gaining an annualized 9.66% per year over the last decade. That's pretty close to the broader market's return over that time and it came with far less volatility.There are other benefits to owning the fund as well. For one thing, NPSAX pays its dividend monthly. Even better is that dividend could be tax-advantaged for many investors. Most preferred stock dividends are considered qualified. This allows them to come in at 15% tax rate. This allows many investors to score a high monthly income -- currently a 4.82% yield -- at a low tax rate.With a Morningstar four-star rating and a low expense ratio of 0.78%, NPSAX offers one of the best active mutual funds to ride out the market's current storm with ease.At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Great Active Mutual Funds for the Current Environment appeared first on InvestorPlace.

  • Parents Push One Rare-Disease Drug Through FDA, Not Its Successor

    Parents Push One Rare-Disease Drug Through FDA, Not Its Successor

    (Bloomberg Opinion) -- For a small biotechnology firm, Sarepta Therapeutics Inc. has made a lot of waves at the Food and Drug Administration. The 2016 approval of its first drug, Exondys 51 – which targets the deadly muscle-wasting disease Duchenne Muscular Dystrophy (DMD) – caused a schism at the agency. A highly organized and vocal group of parents and patients saw hope for boys otherwise resigned to a short and challenging life, helping it gain green-light status, while an agency detractor called the drug an “elegant placebo.” Sarepta’s second drug-approval attempt didn’t go so well. On Monday, the FDA rejected the company’s follow-up drug Vyondys 53, intended for another subset of DMD patients. According to the surprised company, the agency’s principal concerns were with infections related to ports used to infuse the drug, and kidney toxicity observed in pre-clinical models but not seen in the actual trial.If those are the only problems, Vyondys could be back on track in relatively short order. But we don’t know if that’s all there is to it or whether there’s a simple fix because Sarepta didn’t share the FDA’s full rejection letter. The truth is, Sarepta may have a longer, rougher path to further FDA approvals than it previously thought, and its struggles could have a bearing on other drug developers in similar situations.Vyondys likely won’t be approved until at least next year now. That’s not a deal-breaker; the drug was expected to contribute only a modest portion of Sarepta’s future sales. But analysts think the rejection could be about more than a few infections, which may be the reason the company’s shares plunged as much as 20% in early trading Tuesday. Royal Bank of Canada analyst Brian Abrahams suggested in a research note Tuesday that this decision may represent a backlash to Exondys’s approval. It also could be a signal that the agency is upping its safety bar in some cases. There may be something to that. Both Exondys and Vyondys appear able to produce tiny amounts of the protein that boys with DMD lack. It isn’t clear, based on Sarepta’s small trials, that this leads to a real-world benefit. Reliable confirmatory data may not arrive for years.Advocates argue that the FDA should be biased toward approval, when there are no good options even if the data is somewhat scant. Exondys tested the limits of that argument, and it can cost as much as $1 million per year. Potential safety issues for such expensive therapies can make the push for approval harder to support.In the case of Vyondys, the FDA appears to have dug pretty deep for a problem. But if Exondys was an exception and the agency continues to apply a higher standard through the inevitable criticism, another similar medicine of Sarepta’s in development called casamirsen could be in trouble as well. Investors also have to decide if they need to worry about the company’s crucial next generation of drugs, which are gene therapies. Unlike Exondys, which needs to be dosed for years, these medicines could have a long-term impact after just one treatment. Sarepta has produced promising early results for its lead DMD gene therapy, and analysts expect it to generate a billion dollars in sales in 2021. There’s no direct relationship between Vyondys and the gene therapies; the latter work in an entirely different way and don’t have the same kind of efficacy questions. But they are still risky bets that rely on small trials and may require some degree of FDA flexibility.The agency might be in an especially cautious mood in regards to gene therapies after a damaging data fracas recently related to a highly regarded drug made by Novartis AG. Any slowdown for Sarepta would give competitors including Pfizer Inc., Solid Biosciences Inc., and Audentes Therapeutics Inc. opportunities to catch up. At least a chunk of Sarepta’s multi-billion market value likely comes from the perception that it has the magic touch at a more flexible FDA. A previous strength may be turning into a weakness.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at©2019 Bloomberg L.P.

  • Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

    Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

    Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

  • Zacks

    Sarepta Stock Falls as FDA Denies Approval to Golodirsen

    The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

  • Business Wire

    The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance

    Grants to help strengthen health systems and reduce health disparities in underserved communities in Africa, Asia and Latin America

  • Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions
    Investor's Business Daily

    Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions

    The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.

  • Solid Biosciences Surges on DMD Gene Therapy Study Amendments

    Solid Biosciences Surges on DMD Gene Therapy Study Amendments

    Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.

  • Pfizer (NYSE:PFE) Shareholders Have Enjoyed A 20% Share Price Gain
    Simply Wall St.

    Pfizer (NYSE:PFE) Shareholders Have Enjoyed A 20% Share Price Gain

    It might be of some concern to shareholders to see the Pfizer Inc. (NYSE:PFE) share price down 19% in the last month...


    52-Week Company Lows

    Wells Fargo tops list of stocks that have fallen to annual lows Continue reading...